Castle Biosciences, Inc. Common Stock
CSTLCastle Biosciences, Inc. is a dermatologic oncology company focused on developing assays that assist in diagnosing, prognosing, and managing skin cancer. The company specializes in providing molecular diagnostic tests aimed at improving clinical decision-making and patient care for various skin cancers, including melanoma and dermatologic conditions. Founded in 2010, Castle Biosciences is committed to advancing personalized medicine through innovative diagnostic technologies.
Company News
Heather Fisher won an annual stock-picking contest with a 287% average return on three picks, primarily due to an 849% gain in Aehr Test Systems. However, Fisher sold most of her AEHR shares before the dramatic climb, missing out on significant gains. The contest had 42 participants, with 18 beating the S&P 500's 23.3% return.
Castle Biosciences announced results from the largest prospective multicenter study of its DecisionDx-Melanoma i31-SLNB test, presented at SSO 2026. The study of 912 patients found that patients predicted to have less than 5% risk of sentinel lymph node positivity had an actual positivity rate of 2.6%, with only 1.4% in T1b-T2a tumors. Low-risk p...
Castle Biosciences published a prospective validation study in the Journal of the American Academy of Dermatology showing that its AdvanceAD-Tx gene expression profile test can identify patients with moderate-to-severe atopic dermatitis who are significantly more likely to achieve faster and deeper clinical responses with JAK inhibitor therapy. A...
A systematic review and meta-analysis demonstrates that TissueCypher® Barrett's Esophagus test can more accurately identify patients at risk of developing esophageal cancer compared to traditional pathology methods.
Castle Biosciences has been named a Houston Top Workplace for the fifth consecutive year, earning recognition for employee culture, including awards in Employee Appreciation, Employee Well-Being, and Professional Development.
